Imbruvica Market Derives by Therapy, Drugs & Methods, Types, Medical Uses, Manufacturers, Application, key Regions, Growth Drivers & Forecast Period 2019-2025
Global Imbruvica Market Size 2019 evaluates by Growth, Trends, Rate, Value Chain Analysis, Market demands and future prospects 2025. The study covers qualitative and quantitative analysis of the market segmented on the basis of application and region.
Dallas, United States – June 25, 2019 /MarketersMedia/ —
Global Imbruvica Market is poised to remain amply lucrative owing to surged instances of cancers and associated fatalities. Patient preferences for minimal side effects and convenient administration are likely to bode well with impressive growth prospects. Global Imbruvica Market to Witness a CAGR Of 26.5% by 2025 & market is projected to reach USD 31,773.40 million by 2025. Ongoing drug trials and ever-expanding pipeline are likely to favor further impetus. Adroit Market Research (AMR) takes a close dig into concurrent market developments and gauges their reciprocal implications on market, in its freshly added research report titled, ‘Global Imbruvica Market Size by Application and Region, Forecast 2019-2025.
Get more insights at: Global Imbruvica Market 2019-2025
Imbruvica players in the United States include Janssen Pharmaceuticals, Inc. and Pharmacyclics LLC (an AbbVie Company).
Imbruvica is used for the treatment of Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenström’s Macroglobulinemia, Relapsed/Refractory Marginal Zone Lymphoma and Chronic Graft-Versus-Host-Disease. In the U.S. Imbruvica is popularly used for all the above mentioned indications, however in rest of the countries worldwide Imbruvica is majorly used for the treatment of Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Waldenström’s Macroglobulinemia. Thus, Chronic Lymphocytic Leukemia is expected to grow at a highest CAGR of 27.3% by 2025.
In a recent development, medical research and drug company AbbVie has affirmed US FDA’s decision to approve Imbruvica for treating cases of lymphocytic leukemia. The drug when combined with other formulations such as obinutuzumab, rituximab, and bendamustine are posed to render effective efficacy in treating life threatening cancer conditions. Imbruvica is valued as an active BTK inhibitor which eliminates reliance on painful chemotherapy procedures, one of the most sought after cancer therapeutics aid. The drug is commercialized jointly by ace drug veterans AbbVie and Janseen Biotech. These novel developments are likely to spell magnanimous growth in market in the near future. Other prominent players in global imbruvica market comprise J&J, AbbVie, and Pharmacyclics.
Thorough and unbiased research findings documented in the report are headed to offer readers with substantial understanding on market trends and growth trajectory. The report unfurls with a crisp market definition and forays next into market segmentation and competition spectrum. Details on drivers, threats, challenges, and trends have been voraciously discussed to equip readers with substantial competitive advantage allowing them to maneuver remunerative growth strategies and winning objectives. By segmentation global imbruvica market is categorized into application and region. By application mantle cell lymphoma (MCL), chronic lymphocytic leukemia, waldenström’s macroglobulinemia (WM) amongst others are enumerated as major segments. Based on region the market is further demarcated into Europe, Central and South America, Southeast Asia are acknowledged as core regional belts.
For Any Query on the Imbruvica Market:
https://www.adroitmarketresearch.com/researchreport/purchase/839
The report also sheds vital statistical details on competition matrix. Each of the mentioned profiles has been assessed at length and details on company and product portfolios of the mentioned companies have also been thoroughly discussed for profit driven business strategies and goals, in the interest of sustainable revenue pools.
Key Segments of the Global Imbruvica Market
Application Overview, 2015-2025 (USD Million)
• Mantle Cell Lymphoma
• Chronic Lymphocytic Leukaemia
• Waldenström’s Macroglobulinemia
• Relapsed/Refractory Marginal Zone Lymphoma
• Chronic Graft-Versus-Host-Disease
Regional Overview, 2015-2025 (USD Million)
• U.S
• Europe
• India
• Japan
• China
• Southeast Asia
• Central & South America
Get the access of more information through our blog, white paper:
1. White Paper on “Can Imbruvica Change The Cancer Drugs Pattern?”
Imbruvica is basically a cancer medicine which interferes the spread and growth of cancer cells in the human body. The medicine is specifically used to treat marginal zone lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, waldenstrom’s macroglobulinemia, and chronic lymphocytic leukemia. Imbruvica is also used to treat graft-versus-host disease.
Access the complete white paper on Imbruvica Market Report:
https://www.adroitmarketresearch.com/white-paper/can-imbruvica-change-the-cancer-drugs-pattern
2. Blogs on “Imbruvica: History, Guidelines And Side Effects Of The Powerful Drug”:
Imbruvica is also popularly known as Ibrutinib. It was created by a team of scientists at Celera Genomics. It is a mean compound that is used for study of BTK function. It joins the target to ideal for a reagent. This is generally ideal for drugs. In the year 2006 Pharmacyclics picked up Celera’s tiny molecules. This was during the way of obtaining an HDAC-focused program by Celera. The valuation of this is 2 million USD in cash and in terms of stock it is valued as USD 1 million.
Would you like to access the blog on Imbruvica Market Report?
https://www.adroitmarketresearch.com/blogs/imbruvica-history-guidelines-and-side-effects-of-the-powerful-drug
About US:
Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a market’s size, key trends, participants and future outlook of an industry. We intend to become our clients’ knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code– Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.
Contact Info:
Name: Ryan Johnson
Email: Send Email
Organization: Adroit Market Research
Address: 3131 McKinney Ave Ste 600, Dallas, TX 75204, U.S.A
Phone: +1 (214) 884-6068
Website: https://www.adroitmarketresearch.com/industry-reports/imbruvica-market
Source: MarketersMedia
Release ID: 88889273
Copyright © 1999-2013 SproutNews.com
